Giulia Bon

Rome, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Corrigendum to "A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinoma" [Exp Mol Pathol Volume 146, June 2026, 105049].

Corrigendum to "A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinoma" [Exp Mol Pathol Volume 146, June 2026, 105049].

Journal: Experimental and molecular pathology
Published: May 28, 2026

Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer.

Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 17, 2026

A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinoma.

A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinoma.

Journal: Experimental and molecular pathology
Published: January 26, 2026

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer.

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer.

Journal: Molecular oncology
Published: September 24, 2025

Correction to: Role of Hippo pathway dysregulation from gastrointestinal premalignant lesions to cancer.

Correction to: Role of Hippo pathway dysregulation from gastrointestinal premalignant lesions to cancer.

Journal: Journal of translational medicine
Published: May 03, 2024

Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy.

Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 26, 2024

HER2 mutation as an emerging target in advanced breast cancer.

HER2 mutation as an emerging target in advanced breast cancer.

Journal: Cancer science
Published: January 15, 2024

DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study.

DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study.

Journal: Neoplasia (New York, N.Y.)
Published: September 13, 2023

Role of Hippo pathway dysregulation from gastrointestinal premalignant lesions to cancer.

Role of Hippo pathway dysregulation from gastrointestinal premalignant lesions to cancer.

Journal: Journal of translational medicine
Published: July 21, 2023

Hippo pathway dysregulation in gastric cancer: from Helicobacter pylori infection to tumor promotion and progression.

Hippo pathway dysregulation in gastric cancer: from Helicobacter pylori infection to tumor promotion and progression.

Journal: Cell death & disease
Published: October 27, 2022

Corrigendum: Cross-resistance among sequential cancer therapeutics: An emerging issue.

Corrigendum: Cross-resistance among sequential cancer therapeutics: An emerging issue.

Journal: Frontiers in oncology
Published: October 07, 2022

Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma.

Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 09, 2022
Showing 1-12 of 22

Last Updated: 09/26/2026